Akums Drugs and Pharmaceuticals Ltd Q3 FY25 Results
AKUMSQ3 FY25 ResultsAnnounced 7 Feb 2025, 03:42 pm| Metric | Value (₹ Cr) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.0K | 2.2% |
| Total Income | 1.0K | 2.1% |
| Expenditure | 938.70 | 2.1% |
| PBT | 91.05 | 0.6% |
| Net Profit | 66.31 | 0.5% |
| OPM | 2.66% | 0.37pp |
| NPM | 6.47% | 0.10pp |
| EPS | 4.26 | 2.5% |
Akums Drugs and Pharmaceuticals announces robust Q3 FY 25 results with 12% Adj EBITDA and 15% Adj PAT growth
07 Feb 2025 · 7 Feb 2025, 09:16 pm
Summary
Akums Drugs and Pharmaceuticals Ltd. has announced its consolidated financial results for the quarter ended December 31, 2024, delivering a 12% increase in Adjusted EBITDA and a 15% increase in Adjusted PAT on a year on year basis. The company's operating performance was robust, driven by better profitability in the core CDMO segment. The EBITDA improvement shows the company's continued improvement in the product mix. API EBITDA losses reduced significantly in Q3 YoY, although prices of cephalosporin APIs still remain low. The branded formulation business continues to perform well across domestic and export markets.
Key Highlights
- 1
12% increase in Adjusted EBITDA
- 2
15% increase in Adjusted PAT
- 3
Robust operating performance in Q3 FY 25
- 4
Significant reduction in API EBITDA losses
- 5
Continued growth in branded formulation business
Management Comments
Sanjeev Jain
Managing Director
Q3 was an exciting quarter for the company. With our focus on establishing Akums' global CDMO footprint, we took a significant step by securing a €200 million contract. The contract involves manufacture and supply of products to be sold in European markets. We believe this is the first of many partnerships we will undertake to serve the European market in the years to come.
Sandeep Jain
Managing Director
We continue to be the manufacturing partners of choice for pharmaceutical companies. We have started to see volume green shoots in Q3 compared to Q2. We also in-licensed novel products of Triple hair and Caregen in dermatology and metabolic segment to drive future growth.
Informational and educational content only. Not investment advice.